메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

NABR: CITES 상임위원회, 긴꼬리원숭이 사육 실태 조사 결과 공개

워싱턴, 2025년 11월 21일 -- 동물종 거래 실태를 감시하는 국제기구인 CITES 상임위원회(CITES Standing Committee)가 과학적인 절차에 따라 방대한 자료를 제출한 캄보디아 정부에 사의를 표하면서 캄보디아의 동물 사육 방식에 대한 심사 결과를 발표했다. 차기 상임위원회 회의에 앞서 2025년 11월 12일에 발표된 이 보고서는 https://cites.org/eng/sc/79/agenda-documents에서 열람할 수 있다. 보고서는 몇 가지 긍정적인 조사 결과와 함께, 특히 캄보디아의 세관 및 검사 절차가 "국가 단일 창구 시스템을 통해 효과적으로 일원화 및 조정되었을 뿐 아니라, 검사와 문서화를 통해 투명성도 뒷받침한다"라고 기술하고 있다. 또한 보고서에서는 심사 과정 내내 보여준 "캄보디아의 개방성과 협조"에 찬사를 보내는 한편, "캄보디아가 입법 체계를 개선하고, 추적성을 강화하며, CITES 절차를 준수하려는 노력을 기울이고 있다"고 평가했다. 긴꼬리원숭이는 인간과 생물학적으로 매우 비슷해서, 전 세계 생물의학 연구에 꼭 필요한
- 김갑성 기자
- 2025-11-21 01:59
PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting

IRVINE, Calif., Nov. 20, 2025 -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been accepted for oral presentations at the 2025 American Society of Hematology (ASH) Annual Meeting. The abstracts showcase the emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) and r/r B-cell Non-Hodgkin Lymphoma (B-NHL), including patients who
- 김갑성 기자
- 2025-11-20 23:12
HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases

Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception. CHENGDU, China, Nov. 20, 2025 -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), today announced that it has entered into a new contract agreement with the Gates Foundation. HitGen will leverage its industry-leading DNA-encoded library (DEL) platform to identify novel drug leads for the treatment of underserved diseases including tuberculosis and malaria, as well a
- 김갑성 기자
- 2025-11-20 22:30
GENPRIME ACCELERATES GLOBAL GROWTH WITH FERTILITY CENTRE LAUNCHES IN SINGAPORE AND MANILA

The Singapore and New York-headquartered network of clinics expands its Southeast Asia presence, addressing global family-building challenges with technology and empathy NEW YORK, Nov. 20, 2025 -- Rhea Fertility, the reproductive health platform headquartered in Singapore and New York, announces the expansion of GenPrime, its clinic network, with the opening of two flagship fertility centres in Singapore and Manila, the Philippines. The launches mark a major step in scaling GenPrime's next-generation model of fertility care in Southeast Asia, helping couples and individuals pur
- 김갑성 기자
- 2025-11-20 22:00
ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone

BRISBANE, Calif., Nov. 20, 2025 -- ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a $4.6M grant from the California Institute for Regenerative Medicine (CIRM), and has recently reached a key program milestone, having identified a lead compound that meets key development criteria. This funding will further support the advancement of ReviR Therapeutics' HTT-PMS1 genetic medicine program, whereby a small molecule selectively reduces the mRNA of two genes implicated in both the cause and progres
- 김갑성 기자
- 2025-11-20 22:00
Kolmar Korea Named Among TIME's World's Best Companies in Sustainable Growth 2026 for the Second Consecutive Year

Ranked in the Top 7% Among More Than 4,000 Global Corporations, Highlighting Leadership in Eco-Friendly Innovation and Responsible Growth SEOUL, South Korea, Nov. 20, 2025 -- Kolmar Korea, a global cosmetics ODM leader, has been selected for the second consecutive year to TIME's World's Best Companies in Sustainable Growth 2026, reaffirming its position as a global front-runner in eco-friendly and responsible business practices. The rankings were announced on November 13 by TIME in collaboration with global research firm Statista, recognizing the top 500 companies worldwide for
- 김갑성 기자
- 2025-11-20 21:30
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer

[ 메디채널 김갑성 기자 ] The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has met primary endpoints in its phase 3 clinical trial, significantly reducing recurrence risk and improving cure rates. No immunotherapy has been approved globally for gastric cancer perioperative treatment – HANSIZHUANG is poised to address this unmet medical need. SHANGHAI, Nov. 20, 2025 -- Shanghai Henlius Biotech,
- 김갑성 기자
- 2025-11-20 18:52
Clarity Eye Centre Brings SILK™ Laser Eye Technology to Hong Kong

HONG KONG, Nov. 20, 2025 -- Clarity Eye Centre announced the arrival of Johnson & Johnson's next-generation SILK™ Laser Eye Technology, now available to patients in Hong Kong. The clinic is the first in the city to widely offer the ELITA™ Femtosecond Laser, the advanced system that powers SILK™ (Smooth Incision Lenticule Keratomileusis), ushering in a new era of precision and gentle laser vision correction for myopia, with or without astigmatism.[1] SILK™: A Revolutionary Leap in Refractive Surgery SILK™ represents a groundbreaking advancement in vision
- 김갑성 기자
- 2025-11-20 17:34
Gong Yingying: The Next Era of AI Healthcare Requires Trust, Real-World Scenarios, and Universal Accessibility

KUALA LUMPUR, Malaysia, Nov. 20, 2025 -- At the 2025 Fortune Innovation Forum in Kuala Lumpur, global industry leaders and innovators gathered to explore the technologies transforming healthcare. Speaking at the featured roundtable "AI vs. MD," Ms. Gong Yingying, Founder and Chairwoman of Yidu Tech, shared her perspective on the responsible development of AI in healthcare. She was joined by KPJ Healthcare Berhad President & Managing Director Mr. Keat Chyuan Chin and NUHS Clinical Advisory Director Dr. Zubin Daruwalla, with Fortune AI Editor Jeremy Kahn moderating.
- 김갑성 기자
- 2025-11-20 16:52
KHB, MEDICA 2025에서 자동 화학발광 면역분석기 Polaris V150 선보여

[ 메디채널 김갑성 기자 ] 시안, 중국 2025년 11월 20일 -- 글로벌 체외진단(IVD) 솔루션 공급업체 상하이 케후아 바이오엔지니어링(Shanghai Kehua Bio-engineering Co., Ltd., KHB)이 세계적 의료 산업 전시회인 MEDICA 2025에서 최신 소형 화학발광 플랫폼 Polaris V150 자동 화학발광 면역분석기를 선보였다. 올해 KHB 부스의 핵심 전시 제품인 Polaris V150은 자동화 진단 분야에서 이룬 지속적인 혁신을 보여준다. 중소 규모 실험실은 물론 대형 병원과 외부 독립 검사기관의 STAT 및 응급 검사를 지원하도록 설계된 Polaris V150은 효율성과 정밀성, 사용 편의성을 하나의 탁상형 장비에 집약했다. 0.36m²의 설치 공간에 내장형 터치스크린과 컴팩트한 설계로 외부 장치 없이도 실험실에서 강력한 면역분석 기능을 제공한다. 작은 설치 공간과 효율적인 워크플로 0.36m²의 좁은 설치 면적에도 Polaris V150은 시간당 150건의 검사를 처리해 제한된 환경에서도 실험실이 효율적으로 운영될 수 있도록 한다. 시료•시
- 김갑성 기자
- 2025-11-20 15:23

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분